Opinion
Video
Patient Communication and Treatment Adherence in NMIBC
Author(s):
Experts discuss the potential impact of FDA-approved novel delivery systems on patients’ quality of life and treatment adherence in the management of non–muscle-invasive bladder cancer (NMIBC).
Video Player is loading.
Video content above is prompted by the following:
- If they are FDA approved, what impact are the novel delivery systems likely to have on patients’ quality of life? Treatment adherence?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Approaching Corticosteroid Selection With Abiraterone in Patients With High-Risk Localized or Locally Advanced Prostate Cancer
Incorporating Micronized Abiraterone and Low-Fat Meal Dosing: Monitoring Efficacy and Tolerability
The Growing Call for Combination Therapy in NMIBC Treatment
Optimizing NMIBC Treatment Through Sequencing and Patient Preference
Managing Abiraterone Intolerance: Alternative Dosing Strategies in Practice
Decision-Making and Multidisciplinary Counseling for Nodal Involvement on PSMA PET
Rethinking First-Line Treatments: Will BCG Continue to Be the Standard in NMIBC?
In the Pipeline: Novel Treatment Delivery Methods for NMIBC
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
Related Content
